



Reader Offers Additional Zevalin™ Dosing Information

The recent article, “Outpatient Administration of Radiolabeled Monoclonal Antibodies,” (Tuinstra, 2003) lists a platelet count of at least 150,000/mm³ as one of the eligibility criteria for patients to receive ibritumomab tiuxetan (Zevalin™, IDEC Pharmaceuticals, San Diego, CA) therapy. The U.S. Food and Drug Administration-approved criteria in the pack-

age insert (IDEC Pharmaceuticals Corporation, 2002) allows patients with platelet counts of at least 100,000/mm³ but less than 150,000/mm³ to receive Zevalin at a reduced dose of 0.3 mCi/kg to a maximum of 32 mCi. Patients with platelet counts equal to or greater than 150,000/mm³ receive 0.4 mCi/kg to a maximum of 32 mCi for their therapeutic dose.

*Carol P. Curtiss, RN, MSN
Clinical Nurse Specialist Consultant*

*Curtiss Consulting
ccurtiss@shaysnet.com*

IDEC Pharmaceuticals Corporation. (2002). Zevalin™ prescribing information. San Diego, CA: Author

Tuinstra, N. (2003). Clinical Q&A: Outpatient administration of radiolabeled monoclonal antibodies. *Clinical Journal of Oncology Nursing*, 7, 106–108.